Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit

World News: . []

BASEL, Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib during the 3 Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

Dermavant will present Phase 1b data on the safety and efficacy of cerdulatinib for the treatment of atopic dermatitis in both poster format and an oral presentation. The company also will present preclinical data on the suppression of inflammation and skin repigmentation demonstrated by cerdulatinib for the treatment of vitiligo in poster format.

Dermavant is developing topical cerdulatinib as a potential first-in-class steroid-free anti-inflammatory inhibitor of the JAK and Syk pathways that may inhibit the effects of pro-inflammatory cytokines. Given its unique mechanism of action, Dermavant believes that topical cerdulatinib, if approved by the U.S. Food and Drug Administration (FDA), could provide an important topical treatment option for atopic dermatitis as well as other inflammatory skin conditions such as vitiligo, a condition characterized by skin depigmentation for which no FDA-approved treatments currently exist.

Posters, along with dates, times, and locations of data sessions, are highlighted below:

For more information about Dermavant, please visit .

More news and information about Dermavant Sciences, Inc.

Published By:

Globe Newswire: 12:00 GMT Thursday 6th December 2018

Published: .

Search for other references to "dermavant" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us